Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinase drug discovery approaches in chronic myeloproliferative disorders.

Oncogene - 18 Jun 2009

Kumar C, Purandare A V, Lee F Y, Lorenzi M V

Abstract excerpt

Myeloproliferative disorders (MPDs) are clonal malignancies that arise from hematopoietic progenitors and characterized by overproduction of mature, functional blood cells. These disorders can be broadly characterized into Philadelphia chromosome-positive (Ph(+)) or negative (Ph(-)) genetic groupings. Chronic myeloid leukemia (CML) is a Ph(+) MPD that is defined on the basis of its molecular lesion, the BCR-ABL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbazoles
Share to Chronic Disease
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Molecular Structure

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 19421140
DOI: 10.1038/onc.2009.107

Genes

BCR
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinase drug discovery approaches in chronic myeloproliferative disorders.PMID 19421140Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 kinase inhibitors and myeloproliferative disordersSemantic proximity Read ↗

Chronic myeloproliferative disorders: a tyrosine kinase tale.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

JAK2 in myeloproliferative disorders is not just another kinase.Semantic proximity Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Oncogenes in myeloproliferative disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.